Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. du Bois A, et al. Among authors: malander s. Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16. Lancet Oncol. 2016. PMID: 26590673 Free article. Clinical Trial.
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
Corvigno S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, Carlson JW, Fernebro J, Åvall-Lundqvist E, Kannisto P, Hedenfalk I, Malander S, Rolny C, Dahlstrand H, Östman A. Corvigno S, et al. Among authors: malander s. Gynecol Oncol. 2020 Dec;159(3):860-868. doi: 10.1016/j.ygyno.2020.09.041. Epub 2020 Oct 5. Gynecol Oncol. 2020. PMID: 33032823
SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery.
Bååth M, Westbom-Fremer S, Martin de la Fuente L, Ebbesson A, Davis J, Malander S, Måsbäck A, Kannisto P, Hedenfalk I. Bååth M, et al. Among authors: malander s. Mol Cell Oncol. 2020 Sep 5;7(6):1805094. doi: 10.1080/23723556.2020.1805094. Mol Cell Oncol. 2020. PMID: 33235906 Free PMC article.
39 results